Streetbeat News

Products Services

ALT

Altimmune has completed patient enrollment for its Phase 2B trial of pemvidutide in treating MASH, with results expected in Q2 2025. An FDA meeting for its obesity program is set for November 2024, and the company plans to submit IND applications for additional indications in late 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:38 am

BBIO

BridgeBio Pharma has completed enrollment for its Phase 3 FORTIFY study of BBP-418, targeting Limb-girdle Muscular Dystrophy Type 2I/R9. Topline data from the interim analysis is expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:34 am

BHVN

Biohaven has initiated a pivotal Phase 2 study for its TRPM3 antagonist, BHV-2100, aimed at treating acute migraines. The trial will assess the efficacy and safety of two doses and is designed to support FDA registration.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:34 am

TRAW

Traws Pharma announced positive Phase 1 results for its COVID-19 candidate, Ratutrelvir, an oral inhibitor. The drug was well-tolerated and achieved consistent plasma levels without ritonavir. Phase 2a study is expected in H1 2025.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:32 am

AAPL

BABA

MCHI

SBUX

Jim Cramer recommends Apple, Starbucks, and Alibaba as potential beneficiaries of China's new economic stimulus measures. The Chinese government and central bank's actions have sparked a rally in the domestic stock market, with the Shanghai Composite Index rising significantly. The stimulus is expected to positively impact companies with strong ties to China, including Apple, Starbucks, and Alibaba.

Portfolio Pulse from Shanthi Rexaline

September 30, 2024 | 11:27 am

MRNA

Moderna has initiated the dosing of the first US participant in the Nova 301 Phase 3 trial for its investigational norovirus vaccine, mRNA-1403. The trial aims to evaluate the vaccine's efficacy, safety, and immunogenicity, with global recruitment now underway.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:23 am

VSTO

Vista Outdoor's Revelyst brand, Foresight Sports, has reached a patent licensing agreement with Uneekor for portable golf launch monitor technology. This agreement allows Uneekor to use Foresight Sports' patented technologies, acknowledging Foresight's contributions to the industry.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:19 am

NRXP

NRx Pharmaceuticals (NASDAQ:NRXP) has achieved a key milestone with the 12-month stability of its drug NRX-100, indicating a shelf life of over three years. The company is on track to file a New Drug Application (NDA) in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:17 am

EVGN

Lavie Bio, a subsidiary of Evogene, received a grant from the Israel Innovation Authority to advance its 'MicroFermentor' technology for delivering ag-biologicals. This technology aims to reduce costs and extend the viability of beneficial bacteria in agriculture.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:16 am

GTX

Garrett Motion Inc. and China National Heavy Duty Truck Group have signed a Letter of Intent to collaborate on advanced technologies for electric commercial vehicles. They aim to develop next-generation electric powertrains for SinoTruk's product portfolio, with mass production targeted by 2027.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:13 am